Institutions evaluating AI deployment inside Epic face a genuinely different decision than the individual-clinician choice this cluster's separate ChatGPT-for-Clinicians comparison addresses, because at institutional scale both OpenAI and OpenEvidence are pursuing EHR-aware, patient-context capability, and they are converging from opposite architectural starting points that carry different implications for what an institution is actually buying.
Two opposite starting points
OpenAI begins with a broad enterprise AI workspace, ChatGPT Work, Codex, and general organisational connectors spanning SharePoint, Google Drive, Salesforce and Slack, and is adding patient context and official healthcare data onto that existing horizontal foundation. OpenEvidence begins with clinical evidence search specifically, a specialist product built around medical literature and evidence synthesis from the outset, and is adding EHR-aware and visit-related workflows onto that vertical, clinically-specialised foundation, with Epic-linked implementations named at Mount Sinai and Sutter Health, alongside patient-aware clinical-intelligence work underway with Cedars-Sinai.
The comparison, dimension by dimension
Breadth of evidence sources: OpenEvidence's core design centres on medical literature specifically; ChatGPT for Healthcare's Healthcare Public Data plugin spans a wider, more heterogeneous set of source types, medical literature, product labelling, trial registries and operational datasets together. Peer-reviewed-literature emphasis: plausibly stronger in OpenEvidence's architecture given its founding focus, worth confirming directly rather than assumed from either company's general reputation. Patient-record integration: both now offer this at the institutional level, through genuinely different technical routes worth evaluating on their own merits rather than assumed equivalent because both use the word integration. Ambient documentation: neither product's core positioning centres on this specifically, distinguishing both from Heidi and Dragon Copilot's documentation-first architecture covered in this cluster's dedicated three-way comparison. Institutional knowledge: ChatGPT for Healthcare's broader enterprise connector reach extends further into general organisational systems than OpenEvidence's clinically-focused design is built to address. Operational datasets: the CMS and provider-registry sources in OpenAI's nine-source plugin extend into administrative and operational territory OpenEvidence's evidence-first design does not centre. General business tasks and developer tools: squarely ChatGPT for Healthcare's territory through ChatGPT Work and Codex, outside OpenEvidence's specialist scope entirely. Advertising or enterprise business model: worth confirming directly for each product's specific current arrangement, since business-model transparency affects how institutions should weigh any product's incentives. Individual clinician access: both maintain separate individual-level products, distinct from their institutional Epic-linked deployments. And UK localisation: neither currently offers this, the gap running through every comparison in this cluster.
The institutional decision this comparison actually informs
An institution wanting a single governed AI workspace spanning clinical work, research, business intelligence and software development under one vendor relationship is evaluating ChatGPT for Healthcare's genuine strength, breadth and horizontal integration across the organisation's whole technical estate, not only its clinical systems. An institution wanting the deepest, most clinically specialised evidence-retrieval and appraisal capability specifically, with EHR-awareness added as an extension of that core strength rather than the reverse, is evaluating OpenEvidence's genuine strength instead. Neither choice is obviously correct in the abstract; they represent different bets about whether an institution's AI strategy should be organised around one horizontal platform or around best-in-class vertical tools integrated separately into each workflow.
The verdict, held honestly
OpenEvidence likely remains stronger specifically where the core institutional need is specialist medical-evidence interrogation, reflecting its clinical-evidence-first origin. ChatGPT for Healthcare is likely stronger where an institution wants healthcare-specific capability unified with its broader enterprise technology strategy under one governed workspace. Both are converging toward patient-aware, EHR-integrated evidence delivery from genuinely different starting architectures, and an institution's actual priority, specialist depth or platform unification, should decide between them more than either company's current market position or momentum.
Frequently asked questions
Should an institution running Epic deploy both products simultaneously?
Some institutions may reasonably do so, using each for the specific function its architecture suits best, though the governance and integration complexity of running two AI systems with overlapping capability inside the same EHR deserves explicit institutional evaluation rather than being assumed manageable by default.
Does OpenEvidence's clinical-evidence-first origin make it inherently safer for clinical questions?
Not automatically, though it plausibly reflects deeper specialisation in the specific evidence-appraisal task, worth weighing against ChatGPT for Healthcare's own reported evaluation figures directly rather than assumed from architectural origin alone.
Where does this leave UK institutions evaluating either product?
In the same position this cluster names throughout: neither product currently offers UK-specific guidance, medicines or NHS-system integration, making this comparison relevant primarily to institutions' broader AI-strategy thinking rather than to an immediately actionable UK procurement decision today.
How should a procurement committee weigh vendor concentration risk here?
Directly and explicitly: choosing ChatGPT for Healthcare deepens reliance on OpenAI across clinical and non-clinical systems alike, while choosing OpenEvidence keeps AI vendor exposure more narrowly scoped to clinical evidence specifically, a genuine trade-off between platform convenience and vendor-concentration risk worth naming in any board-level procurement discussion.